**IAP Assessment Form Immunoglobulin Replacement Therapy:**

For **new** therapy or **review** of existing therapy

**Complete all relevant patient details. Incomplete forms will be rejected and funding for immunoglobulin may be in jeopardy.**

**Once complete, submit to** [**add-tr.iap-eastofengland@nhs.net**](mailto:add-tr.iap-eastofengland@nhs.net)

|  |
| --- |
| **The Immunology specialist assessment panel meets weekly.**  **Details from: cuh.add-tr.eastofeng-iapcoodinator.nhs.net** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Demographic details:** | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Name of requesting Trust: | | | | | | | | | Choose an item. | | | | | | | | | | | | | | | | | | |
| Patient Initials: | | | | | | | | |  | | | | | | | DOB: | | | | | | | | | Click here to enter text. | | |
| NHS number (essential): | | | | | | | | |  | | | | | | | Height (cm) | | | | | | | | | Click here to enter text. | | |
| Local hospital #: | | | | | | | | |  | | | | | | | Weight (kg) | | | | | | | | | Click here to enter text. | | |
| If commenced / recommended by another SRIAP or immunology centre, detail below: | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Immunological diagnosis** *(please indicate if primary or secondary and give details)* | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Select immunodeficiency type  Choose an item. | | | | | | | | | | | Primary | | | Details: | | | | | | | | | | | | | |
| Secondary | | |
| Specific | | |
| If secondary details of current medication/treatment that can cause immunosuppression | | | | | | | | | | |  | | |  | | | | | | | | | | | | | |
| Immunoglobulin replacement commenced Y/N | | | | | | | | | | | Yes | | | If yes, date commenced | | | | | | | | | | | | | |
| No | | |
| Immunoglobulin product  (if commenced) | | | | | | | | | | | Brand | | | If established | | | | | | | | | | | | | |
| Dose | | |  | | | | | | grams | | | | | | | |
| Frequency | | | Every | | | | | | | | | | | | | |
| Route | | | SC or IV | | | | | | | | | | | | | |
| **Co-morbidities** *(please add extra lines if required)* | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Bronchiectasis | | | | | | | Y/N | | | Additional Co-morbidities – include below; | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Is the patient under the care of a respiratory physician? | | | | | | | | | | | | | | | | | | Y/N | | |  | | | | | | |
| Respiratory Physician’s name and Trust: | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Immunoglobulin levels Pre Commencing Immunoglobulin Therapy** | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| IgG | | Result | |  | | | | | | | | | | | | | | Date | | | | | | | Click here to enter a date. | | |
| IgA | | Result | |  | | | | | | | | | | | | | | Date | | | | | | | Click here to enter a date. | | |
| IgM | | Result | |  | | | | | | | | | | | | | | Date | | | | | | | Click here to enter a date. | | |
| **Immunoglobulin level results (most recent)** | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| IgG | Result | | | |  | | | | | | | | | | | | | Date | | | | | | | Click here to enter a date. | | |
| IgA | Result | | | |  | | | | | | | | | | | | | Date | | | | | | | Click here to enter a date. | | |
| IgM | Result | | | |  | | | | | | | | | | | | | Date | | | | | | | Click here to enter a date. | | |
| **Immunisation history:** | | | | | | | | | | | | | | | | | | Pre-vaccination levels | | | | | | | Post vaccination levels | | |
| *Haemophilus influenzae type B* | | | | | | | | | | | | | | | | | |  | | | | | | |  | | |
| Serotype specific pneumococcal (number of serotypes >0.35) | | | | | | | | | | | | | | | | | |  | | | | | | |  | | |
|  | | | | |  | | | | | | | | | | | | | | | | | | | | | | |
| **Infection/treatment history** | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Antibiotic prophylaxis (AbP) | | | | | | | | | | | | Y/N | | | | | | | If Y, start date: | | | | | | | | |
| Please give details of antibiotic and dose | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Allergies to antibiotics | | | | | | | | Y/N | | | | | If Y please list: | | | | | | | |  | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| History in last 12 months | | | | | | | | | | | |  | | | | | | | | | | |  | | | | |
| Total number | | | | | | | | | | | Number while on AbP | | | | |
| Chest infections | | | | | | | | | | | |  | | | | | | | | | | |  | | | | |
| Radiologically proven pneumonia | | | | | | | | | | | |  | | | | | | | | | | |  | | | | |
| Sinus/URT/ear infections | | | | | | | | | | | |  | | | | | | | | | | |  | | | | |
| Courses of antibiotics | | | | | | | | | | | | Oral | | | | | IV | | | | | Oral | | | | | IV |
| Hospital admissions with infection | | | | | | | | | | | |  | | | | | | | | | | | | | | | |
| Details of other significant infections | | | | | | | | | | | |  | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Microbiology /Organisms identified *(please add extra lines if required)* | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Organism (e.g. *Haemophilus influenzae*) | | | | | | | | | | | | | | | Sample/Site (e.g. Sputum/BAL) | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | |  | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | |  | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Referring clinician** | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Name | | | | | | | | | |  | | | | | | | | | | | | | | | | | |
| Hospital | | | | | | | | | |  | | | | | | | | | | | | | | | | | |
| NHS e-mail address\* | | | | | | | | | |  | | | | | | | | | | | | | | | | | |
| Contact telephone number | | | | | | | | | |  | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Relating to CAR-T (chimeric antigen receptor T-cell) therapy**; complete if applicable | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Indicate which particular NICE-approved CAR-T therapy has been employed\* | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| NICE TA677 | | | Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma | | | | | | | | | | | | | | | | | | | | | | | Tick | |
| NICE TA872 | | | **Axicabtagene ciloleucel** for treating large diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | | | | | | | | | | | | | | | | | | | | | | | Tick | |
| NICE TA895 | | | **Axicabtagene ciloleucel** for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | | | | | | | | | | | | | | | | | | | | | | | Tick | |
| NICE TA893 | | | **Brexucabtagene autoleucel** for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over | | | | | | | | | | | | | | | | | | | | | | | Tick | |
| NICE TA554 | | | **Tisagenlecleucel** for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years | | | | | | | | | | | | | | | | | | | | | | | Tick | |
| NICE TA567 | | | **Tisagenlecleucel** for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies | | | | | | | | | | | | | | | | | | | | | | | Tick | |
| \*This data is required to be collected by NICE | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Immunology MDT** | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Submitted (date) | | | | | | | | | | | | | | | | | | | | | | | | Click here to enter a date. | | | |
| Reviewed at (date of meeting) | | | | | | | | | | | | | | | | | | | | | | | | Click here to enter a date. | | | |
| Outcome: | | | | | | | | | | | | | | | | | | | | | | | | Click here to enter a date. | | | |
| Communication to: | | | | | |  | | | | | | | | | | | | | | | | | | | | | |